GC
ICPT

Grimes & Company’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Grimes & Company’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,350
Closed -$291K – 277
2019
Q4 		$291K Buy
+2,350
New +$210K 0.02% 218

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Grimes & Company's ICPT Position: Q1 2020 in Review

Grimes & Company sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2020, closing a stake of 2,350 shares — an estimated $291K sold.

Grimes & Company first reported a position in ICPT in Q4 2019 and held it in 1 quarter. The position peaked at $291K in Q4 2019. 188 funds tracked by Wall St. Rank hold ICPT as of Q1 2020.

  • Grimes & Company reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Grimes & Company sold 2,350 Intercept Pharmaceuticals, Inc. shares in Q1 2020, an estimated $291K.
  • Grimes & Company first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • Grimes & Company's Intercept Pharmaceuticals, Inc. position peaked at $291K in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2020.

Based on Grimes & Company's 13F filing for Q1 2020, filed 5 May 2020.